The Hyderabad-based Dr Reddy's Laboratories has launched Hyalosyn (sodium hyaluronate), an intra-articular injection that provides relief from knee-joint stiffness and immobility among patients suffering from severe osteoarthritis. Osteoarthritis is a widely prevalent disease. More than 90 per cent of people above the age of 45 are estimated to show signs of this disease, and it is the leading cause of disability in people above the age of 65.
Hyaluronic acid, the active substance in Hyalosyn, a naturally occurring substance found in Synovial fluid, surrounds the joints. Hyaluronic acid acts as a lubricant that enables bones to move smoothly over each other and also acts as a shock absorber for joints. Hyalosyn is an emerging therapy for osteoarthritis. Hyalosyn will provide the much-needed relief to patients suffering from severe osteoarthritis and will enable them to resume their daily activities.
Hyalosyn will be marketed as a sterile, pre-filled syringe containing 20 mg/2ml of sodium hyaluronate. Hyalosyn is being launched under a co-marketing arrangement with Gland Pharma, a pharmaceutical company in Hyderabad well known for the production of pre-filled injectables. The introduction of Hyalosyn would further strengthen the company's arthritis franchise in which it is already a leading player in the domestic market.